DK2408807T3 - Fremgangsmåde til terapeutisk anvendelse - Google Patents

Fremgangsmåde til terapeutisk anvendelse Download PDF

Info

Publication number
DK2408807T3
DK2408807T3 DK10710017.4T DK10710017T DK2408807T3 DK 2408807 T3 DK2408807 T3 DK 2408807T3 DK 10710017 T DK10710017 T DK 10710017T DK 2408807 T3 DK2408807 T3 DK 2408807T3
Authority
DK
Denmark
Prior art keywords
therapeutic use
therapeutic
Prior art date
Application number
DK10710017.4T
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Maria Pihlgren
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Application granted granted Critical
Publication of DK2408807T3 publication Critical patent/DK2408807T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK10710017.4T 2009-03-18 2010-03-18 Fremgangsmåde til terapeutisk anvendelse DK2408807T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16116509P 2009-03-18 2009-03-18
US25602809P 2009-10-29 2009-10-29
PCT/EP2010/053519 WO2010106127A2 (en) 2009-03-18 2010-03-18 Method for therapeutic use

Publications (1)

Publication Number Publication Date
DK2408807T3 true DK2408807T3 (da) 2021-08-09

Family

ID=42376556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10710017.4T DK2408807T3 (da) 2009-03-18 2010-03-18 Fremgangsmåde til terapeutisk anvendelse

Country Status (17)

Country Link
US (1) US20100285108A1 (da)
EP (2) EP3978517A1 (da)
JP (2) JP2012520852A (da)
KR (1) KR20120004994A (da)
CN (1) CN102428101B (da)
AU (1) AU2010224824B2 (da)
CA (1) CA2755683A1 (da)
DK (1) DK2408807T3 (da)
ES (1) ES2885398T3 (da)
HU (1) HUE055739T2 (da)
IL (1) IL214919A (da)
MX (1) MX2011009654A (da)
PT (1) PT2408807T (da)
RU (1) RU2579659C2 (da)
SG (1) SG174871A1 (da)
SI (1) SI2408807T1 (da)
WO (1) WO2010106127A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2440234A4 (en) * 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
KR20160099732A (ko) * 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
MX354662B (es) * 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
CA2872656A1 (en) * 2012-05-08 2013-11-14 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+t cell populations
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
SG11201705982PA (en) * 2015-01-23 2017-08-30 Helix Biopharma Corp Antibody-urease conjugates for therapeutic purposes
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
AR113792A1 (es) * 2017-10-25 2020-06-10 Janssen Pharmaceuticals Inc Composiciones de péptidos tau fosforilados y sus usos
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
BR112021014794A2 (pt) 2019-02-08 2021-10-05 Ac Immune S.A. Método de administração segura de vacina de peptídeo de tau fosforilada
EP3965817A4 (en) 2019-04-24 2023-11-22 Janssen Pharmaceuticals, Inc. HETEROLOGICAL ADMINISTRATION OF TAU VACCINES
TW202110425A (zh) * 2019-05-21 2021-03-16 瑞士商Ａｃ 免疫有限公司 抗Ａβ疫苗治療
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2024211543A1 (en) 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5843779A (en) * 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
CA2415919A1 (en) * 2000-07-11 2002-01-17 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
CA2511606A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1494000A1 (en) * 2003-07-02 2005-01-05 Sicpa Holding S.A. Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
ES2539262T3 (es) * 2004-02-20 2015-06-29 Ac Immune Sa Métodos y composiciones que comprenden construcciones supramoleculares
ES2551604T3 (es) * 2005-12-12 2015-11-20 Ac Immune S.A. Vacuna terapéutica
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція

Also Published As

Publication number Publication date
AU2010224824B2 (en) 2014-02-20
ES2885398T3 (es) 2021-12-13
EP2408807B1 (en) 2021-07-21
HUE055739T2 (hu) 2021-12-28
IL214919A0 (en) 2011-11-30
RU2579659C2 (ru) 2016-04-10
CN102428101B (zh) 2016-03-02
IL214919A (en) 2016-10-31
AU2010224824A1 (en) 2011-09-22
SG174871A1 (en) 2011-11-28
JP2012520852A (ja) 2012-09-10
JP2015221809A (ja) 2015-12-10
MX2011009654A (es) 2011-10-12
PT2408807T (pt) 2021-09-03
CA2755683A1 (en) 2010-09-23
EP3978517A1 (en) 2022-04-06
CN102428101A (zh) 2012-04-25
WO2010106127A2 (en) 2010-09-23
RU2011141889A (ru) 2013-04-27
EP2408807A2 (en) 2012-01-25
AU2010224824A2 (en) 2011-09-22
WO2010106127A3 (en) 2011-03-31
US20100285108A1 (en) 2010-11-11
KR20120004994A (ko) 2012-01-13
SI2408807T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
CY2017047I2 (el) Συνδυαστικη θεραπεια για χαπ
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
EP2427572A4 (en) SEQUENCING METHODS
BR112012015988A2 (pt) método
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
EP2509515A4 (en) WITHERS
BRPI1012526A2 (pt) método
BRPI1010705A2 (pt) método
EP2435825A4 (en) METHODS OF TREATING DISEASES
BRPI0917684A2 (pt) método terapêutico homeopático
DK2310613T3 (da) Forbedret brudled til stigrør
DK2513288T3 (da) Indretning til kontinuerlig dyrkning
BRPI1012532A2 (pt) método
BR112013009024A2 (pt) método
BR112012023891A2 (pt) método
EP2530464A4 (en) METHOD FOR MEASURING -AMYLOID
BRPI1009350A2 (pt) método
ITPD20090053U1 (it) Paradordi per banchine
PL2488158T3 (pl) Ulepszone lecznicze preparaty aerozolowe
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BR112012033000A2 (pt) método
EP2490704A4 (en) THERAPEUTIC COMPOSITION